<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Haemonetics Corporation — News on 6ix</title>
<link>https://6ix.com/company/haemonetics-corporation</link>
<description>Latest news and press releases for Haemonetics Corporation on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Fri, 24 Apr 2026 10:20:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/haemonetics-corporation" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68357bf878dffbe2df0f98d9.webp</url>
<title>Haemonetics Corporation</title>
<link>https://6ix.com/company/haemonetics-corporation</link>
</image>
<item>
<title>New Study Highlights Safety and Efficacy Profile of Haemonetics' VASCADE MVP® XL in Large-Bore Venous Access Closure Procedures</title>
<link>https://6ix.com/company/haemonetics-corporation/news/new-study-highlights-safety-and-efficacy-profile-of-haemonetics-vascade-mvpr-xl-in-large-bore-venous-access-closure-procedures</link>
<guid isPermaLink="true">https://6ix.com/company/haemonetics-corporation/news/new-study-highlights-safety-and-efficacy-profile-of-haemonetics-vascade-mvpr-xl-in-large-bore-venous-access-closure-procedures</guid>
<pubDate>Fri, 24 Apr 2026 10:20:00 GMT</pubDate>
<description>Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes, today announced the publication of a new study comparing its VASCADE MVP® XL vascular closure system with the VASCADE MVP® venous vascular closure system in the context of large‐bore venous access closure procedures. This study, "VASCADE MVP-XL Versus VASCADE MVP for Large-Bore Venous Access-Site Closure in Electrophysiology Procedures: A Singl</description>
</item>
<item>
<title>Haemonetics Sets Date for Publishing Fourth Quarter and Fiscal Year 2026 Results: May 7, 2026</title>
<link>https://6ix.com/company/haemonetics-corporation/news/haemonetics-sets-date-for-publishing-fourth-quarter-and-fiscal-year-2026-results-may-7-2026-6</link>
<guid isPermaLink="true">https://6ix.com/company/haemonetics-corporation/news/haemonetics-sets-date-for-publishing-fourth-quarter-and-fiscal-year-2026-results-may-7-2026-6</guid>
<pubDate>Wed, 01 Apr 2026 20:05:00 GMT</pubDate>
<description>Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish fourth quarter fiscal year 2026 financial results at 6:00 am ET on Thursday, May 7, 2026. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on May 7, 2026.</description>
</item>
<item>
<title>Haemonetics Receives FDA Approval for Expanded Labeling of the VASCADE MVP® XL Venous Vascular Closure System</title>
<link>https://6ix.com/company/haemonetics-corporation/news/haemonetics-receives-fda-approval-for-expanded-labeling-of-the-vascade-mvpr-xl-venous-vascular-closure-system</link>
<guid isPermaLink="true">https://6ix.com/company/haemonetics-corporation/news/haemonetics-receives-fda-approval-for-expanded-labeling-of-the-vascade-mvpr-xl-venous-vascular-closure-system</guid>
<pubDate>Mon, 30 Mar 2026 20:15:00 GMT</pubDate>
<description>Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes, today announced U.S. Food and Drug Administration (FDA) approval to expand the labeling for the VASCADE MVP® XL venous vascular closure system to include procedures using 10-14F inner diameter (ID) and up to 17F outer diameter (OD) procedural sheaths. With this label expansion, the VASCADE MVP XL system is approved for larger sheaths used in ma</description>
</item>
<item>
<title>Haemonetics Receives FDA Clearance for NexSys® PCS Plasma Collection System with Persona® PLUS Technology</title>
<link>https://6ix.com/company/haemonetics-corporation/news/haemonetics-receives-fda-clearance-for-nexsysr-pcs-plasma-collection-system-with-personar-plus-technology</link>
<guid isPermaLink="true">https://6ix.com/company/haemonetics-corporation/news/haemonetics-receives-fda-clearance-for-nexsysr-pcs-plasma-collection-system-with-personar-plus-technology</guid>
<pubDate>Mon, 23 Feb 2026 21:15:00 GMT</pubDate>
<description>Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance for the NexSys PCS® Plasma Collection System with Persona® PLUS technology. Persona PLUS represents the next generation of Haemonetics' proprietary and patented Persona technology that tailors plasma collections to each donor for improved average plasma volume per donation</description>
</item>
<item>
<title>Haemonetics to Present at Raymond James 47th Annual Institutional Investors Conference</title>
<link>https://6ix.com/company/haemonetics-corporation/news/haemonetics-to-present-at-raymond-james-47th-annual-institutional-investors-conference</link>
<guid isPermaLink="true">https://6ix.com/company/haemonetics-corporation/news/haemonetics-to-present-at-raymond-james-47th-annual-institutional-investors-conference</guid>
<pubDate>Fri, 20 Feb 2026 21:05:00 GMT</pubDate>
<description>Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will participate in a fireside chat with investors at the Raymond James 47th Annual Institutional Investors Conference on Monday, March 2, 2026 at 10:25 a.m. ET.</description>
</item>
<item>
<title>Haemonetics Corporation Announces Third Quarter Fiscal 2026 Financial Results Available on Investor Relations Website</title>
<link>https://6ix.com/company/haemonetics-corporation/news/haemonetics-corporation-announces-third-quarter-110000372</link>
<guid isPermaLink="true">https://6ix.com/company/haemonetics-corporation/news/haemonetics-corporation-announces-third-quarter-110000372</guid>
<pubDate>Thu, 05 Feb 2026 11:00:00 GMT</pubDate>
<description>Haemonetics Corporation (NYSE: HAE) announced that financial results for its third quarter fiscal year 2026, which ended December 27, 2025, are available on the Company's Investor Relations website at www.haemonetics.com.</description>
</item>
<item>
<title>EQT Life Sciences to exit Vivasure Medical via sale to Haemonetics</title>
<link>https://6ix.com/company/haemonetics-corporation/news/eqt-life-sciences-to-exit-vivasure-medical-via-sale-to-haemonetics</link>
<guid isPermaLink="true">https://6ix.com/company/haemonetics-corporation/news/eqt-life-sciences-to-exit-vivasure-medical-via-sale-to-haemonetics</guid>
<pubDate>Mon, 12 Jan 2026 06:48:00 GMT</pubDate>
<description>EQT Life Sciences is pleased to announce that the LSP Health Economics Fund has exited Vivasure Medical Limited ("Vivasure" or the "Company"), a Galway, Ireland-based company pioneering next-generation technology for percutaneous vessel closure, through a sale to Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes.</description>
</item>
<item>
<title>Vivasure Medical Announces Acquisition by Haemonetics Corporation</title>
<link>https://6ix.com/company/haemonetics-corporation/news/vivasure-medical-announces-acquisition-by-haemonetics-corporation</link>
<guid isPermaLink="true">https://6ix.com/company/haemonetics-corporation/news/vivasure-medical-announces-acquisition-by-haemonetics-corporation</guid>
<pubDate>Fri, 09 Jan 2026 13:00:00 GMT</pubDate>
<description>GALWAY, Ireland, January 09, 2026--Vivasure Medical®, a company pioneering novel fully absorbable technology for percutaneous vessel closure, today announced that the company has been acquired by Haemonetics Corporation (NYSE: HAE) in a transaction valued up to €185M (~$215M) on completion of certain milestones.</description>
</item>
<item>
<title>Haemonetics Acquires Vivasure Medical Limited</title>
<link>https://6ix.com/company/haemonetics-corporation/news/haemonetics-acquires-vivasure-medical-limited-111500431</link>
<guid isPermaLink="true">https://6ix.com/company/haemonetics-corporation/news/haemonetics-acquires-vivasure-medical-limited-111500431</guid>
<pubDate>Fri, 09 Jan 2026 11:15:00 GMT</pubDate>
<description>Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes, today announced the acquisition of Vivasure Medical Limited (Vivasure), a Galway, Ireland-based company pioneering next-generation technology for percutaneous vessel closure.</description>
</item>
<item>
<title>Haemonetics Sets Date for Publishing Third Quarter Fiscal Year 2026 Results: February 5, 2026</title>
<link>https://6ix.com/company/haemonetics-corporation/news/haemonetics-sets-date-publishing-third-231700550</link>
<guid isPermaLink="true">https://6ix.com/company/haemonetics-corporation/news/haemonetics-sets-date-publishing-third-231700550</guid>
<pubDate>Wed, 07 Jan 2026 23:17:00 GMT</pubDate>
<description>Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish third quarter fiscal year 2026 financial results at 6:00 am ET on Thursday, February 5, 2026. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on February 5, 2026.</description>
</item>
<item>
<title>Haemonetics to Present at 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/haemonetics-corporation/news/haemonetics-present-44th-annual-j-110000098</link>
<guid isPermaLink="true">https://6ix.com/company/haemonetics-corporation/news/haemonetics-present-44th-annual-j-110000098</guid>
<pubDate>Fri, 02 Jan 2026 11:00:00 GMT</pubDate>
<description>Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 13, 2026 at 7:30 am Pacific Time.</description>
</item>
<item>
<title>UPDATE Headwall Appoints Tim Spang as Chief Executive Officer</title>
<link>https://6ix.com/company/haemonetics-corporation/news/update-headwall-appoints-tim-spang-as-chief-executive-officer</link>
<guid isPermaLink="true">https://6ix.com/company/haemonetics-corporation/news/update-headwall-appoints-tim-spang-as-chief-executive-officer</guid>
<pubDate>Thu, 13 Nov 2025 18:59:00 GMT</pubDate>
<description>Bolton, Massachusetts, Nov. 13, 2025 (GLOBE NEWSWIRE) -- The Board of Directors of Headwall Group (“Headwall”), a leader in advanced hyperspectral imaging technology and a portfolio company of private equity firm Arsenal Capital Partners, today announced that it has appointed Tim Spang as Chief Executive Officer. Spang brings decades of operational experience and a proven record of building high-performance, growth-oriented organizations. He joined Headwall in June 2025 and has most recently ser</description>
</item>
<item>
<title>Headwall Appoints Tim Spang as Chief Executive Officer</title>
<link>https://6ix.com/company/haemonetics-corporation/news/headwall-appoints-tim-spang-as-chief-executive-officer</link>
<guid isPermaLink="true">https://6ix.com/company/haemonetics-corporation/news/headwall-appoints-tim-spang-as-chief-executive-officer</guid>
<pubDate>Thu, 13 Nov 2025 15:59:00 GMT</pubDate>
<description>Bolton, Massachusetts, Nov. 13, 2025 (GLOBE NEWSWIRE) -- The Board of Directors of Headwall Group (“Headwall”), a leader in advanced hyperspectral imaging technology and a portfolio company of private equity firm Arsenal Capital Partners, today announced that it has appointed Tim Spang as Chief Executive Officer. Spang brings decades of operational experience and a proven record of building high-performance, growth-oriented organizations. He joined Headwall in June 2025 and has most recently ser</description>
</item>
<item>
<title>Haemonetics Corporation Announces Second Quarter Fiscal 2026 Financial Results Available on Investor Relations Website</title>
<link>https://6ix.com/company/haemonetics-corporation/news/haemonetics-corporation-announces-second-quarter-110000008</link>
<guid isPermaLink="true">https://6ix.com/company/haemonetics-corporation/news/haemonetics-corporation-announces-second-quarter-110000008</guid>
<pubDate>Thu, 06 Nov 2025 11:00:00 GMT</pubDate>
<description>Haemonetics Corporation (NYSE: HAE) announced that financial results for its second quarter fiscal year 2026, which ended September 27, 2025, are available on the Company's Investor Relations website at www.haemonetics.com.</description>
</item>
<item>
<title>Haemonetics Sets Date for Publishing Second Quarter Fiscal Year 2026 Results: November 6, 2025</title>
<link>https://6ix.com/company/haemonetics-corporation/news/haemonetics-sets-date-publishing-second-200500985</link>
<guid isPermaLink="true">https://6ix.com/company/haemonetics-corporation/news/haemonetics-sets-date-publishing-second-200500985</guid>
<pubDate>Thu, 09 Oct 2025 20:05:00 GMT</pubDate>
<description>Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish second quarter fiscal year 2026 financial results at 6:00 am ET on Thursday, November 6, 2025. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on November 6, 2025.</description>
</item>
<item>
<title>Haemonetics 1st Quarter Fiscal Year 2026 Earnings Release Available on Investor Relations Website</title>
<link>https://6ix.com/company/haemonetics-corporation/news/haemonetics-1st-quarter-fiscal-2026-100000581</link>
<guid isPermaLink="true">https://6ix.com/company/haemonetics-corporation/news/haemonetics-1st-quarter-fiscal-2026-100000581</guid>
<pubDate>Thu, 07 Aug 2025 10:00:00 GMT</pubDate>
<description>Haemonetics Corporation (NYSE: HAE) announced that financial results for its first quarter fiscal year 2026, which ended June 28, 2025, are available on its Investor Relations website.</description>
</item>
<item>
<title>Integer Appoints Michael Coyle to Board of Directors</title>
<link>https://6ix.com/company/haemonetics-corporation/news/integer-appoints-michael-coyle-to-board-of-directors-1</link>
<guid isPermaLink="true">https://6ix.com/company/haemonetics-corporation/news/integer-appoints-michael-coyle-to-board-of-directors-1</guid>
<pubDate>Thu, 10 Jul 2025 20:52:00 GMT</pubDate>
<description>~ New Director Brings Extensive Medical Device Industry Leadership and Technology Experience to Integer Board ~ PLANO, Texas, July 10, 2025 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE: ITGR), a leading global medical device contract development and manufacturing organization (CDMO), today announced it has appointed Michael Coyle to its Board of Directors. Coyle brings more than 40 years of leadership in the medical device industry to Integer and joins the Board as a member of the Audi</description>
</item>
<item>
<title>Haemonetics Sets Date for Publishing First Quarter Fiscal Year 2026 Results: August 7, 2025</title>
<link>https://6ix.com/company/haemonetics-corporation/news/haemonetics-sets-date-publishing-first-200500961</link>
<guid isPermaLink="true">https://6ix.com/company/haemonetics-corporation/news/haemonetics-sets-date-publishing-first-200500961</guid>
<pubDate>Wed, 09 Jul 2025 20:05:00 GMT</pubDate>
<description>Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish first quarter fiscal year 2026 financial results at 6:00 am ET on Thursday, August 7, 2025. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on August 7, 2025.</description>
</item>
<item>
<title>Haemonetics to Present at Goldman Sachs 46th Annual Global Healthcare Conference</title>
<link>https://6ix.com/company/haemonetics-corporation/news/haemonetics-present-goldman-sachs-46th-100000529</link>
<guid isPermaLink="true">https://6ix.com/company/haemonetics-corporation/news/haemonetics-present-goldman-sachs-46th-100000529</guid>
<pubDate>Fri, 30 May 2025 10:00:00 GMT</pubDate>
<description>Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will participate in a fireside chat with investors at the Goldman Sachs 46th Annual Global Healthcare Conference on Monday, June 9, 2025 at 8:40 a.m. ET.</description>
</item>
<item>
<title>Haemonetics 4th Quarter and Fiscal Year 2025 Earnings Release Available on Investor Relations Website</title>
<link>https://6ix.com/company/haemonetics-corporation/news/haemonetics-4th-quarter-fiscal-2025-100000005</link>
<guid isPermaLink="true">https://6ix.com/company/haemonetics-corporation/news/haemonetics-4th-quarter-fiscal-2025-100000005</guid>
<pubDate>Thu, 08 May 2025 10:00:00 GMT</pubDate>
<description>Haemonetics Corporation (NYSE: HAE) announced that financial results for its fourth quarter and fiscal year 2025, which ended March 29, 2025, are available on its Investor Relations website.</description>
</item>
</channel>
</rss>